Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use

Anchoring Intermittent Long Acting Antimicrobials to Medication for Opioid Use Disorder Treatment to Facilitate Structured Transitions of Care for People Who Use Drugs Admitted to the Hospital With Invasive Infections

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05521880

Acronym

AIM-STOP

Enrollment

Registered

2022-08-30

Start date

2024-07-15

Completion date

2025-05-23

Last updated

2026-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance Use Disorders, Infection, Soft Tissue, Bacteremia, Osteomyelitis Acute, Septic Arthritis

Keywords

OPAT, oritavancin

Brief summary

Standard of care for patients with opioid use disorder and complicated infections is discharge to subacute nursing facilities on IV antibiotics until completion of treatment course. We aim to determine the efficacy of an alternative strategy using intermittent outpatient oritavancin therapy dosed weekly combined with initiation and continuation of medication assisted treatment for opioid use disorder for completion of antimicrobial therapy in a 12 week prospective, open-label study. Patients hospitalized for a drug use related infection and thought to need prolonged parenteral antimicrobial therapy will be assessed by a substance use consultant and Infectious Diseases service. If they are not on Medication for Opioid Use Disorder (MOUD), they will be assessed for initiation of MOUD. A collaborative multidisciplinary discharge planning process will be initiated and will involve linkage to care. If they have an infection with a gram positive organism, and are thought to be clinically stable for hospital discharge, they will be assessed for appropriateness for oritavancin and first dose will be administered prior to discharge. They will have an intake into an opioid treatment program where they can access collocated services and will be discharged with linkage to care through a peer recovery coach. They will be assessed in this collocated clinic post discharge for optimization of MOUD and progress of infection and subsequent dose/s of oritavancin will be administered. Patients will be followed for 12 weeks for cure/completion of therapy and MOUD outcomes.

Interventions

DRUGOritavancin

Sequential therapy with weekly doses of oritavancin 1200 mg in stable, discharge appropriate patients with opioid use related invasive infections collocated in setting of treatment for opioid use disorder

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 88 Years

Healthy volunteers

Inclusion criteria

* Age 18 years old * Able and willing to sign consent * Ongoing opioid use defined by self report of use of non prescription opioids within 3 months of hospitalization * Has infection determined to be from opioid/drug use and needed prolonged parenteral antimicrobial therapy * Gram positive organism as causal pathogen and expected to be sensitive to oritavancin * Deemed to be clinically stable for discharge (i.e no need for surgical intervention, with stable vital signs,afebrile and bacteremia cleared if present at admission for at least 72 hours) * Not on opioid agonist therapy at admission to hospital and willing to initiate medication for opioid use disorder, which includes methadone/suboxone * Willing and able to follow up for MOUD in colocated clinic site * If female, the patient is surgically sterile, postmenopausal, or, if of childbearing potential, agrees to use at least 2 highly effective methods of birth control (e.g. prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, barrier methods, abstinence) for the duration of the study until 60 days after study drug administration, or male partner sterilization alone

Exclusion criteria

* Known immediate hypersensitivity to oritavancin or glycopeptides * Decompensated liver disease (Childs Pugh B or C) or Stage IV/V chronic kidney disease or acute kidney injury with creatinine clearance \<30 * Unable to comply with research study visits * Poor venous access not allowing screening laboratory collection * Have any condition that the investigator considers a contraindication to study participation * Pregnant or breastfeeding woman * Require valve replacement surgery or have prosthetic material in body including prosthetic joints or non bioprosthetic valves. * Polymicrobial infection * Multisite infection- defined as \>2 different organ system involvement or non-contiguous sites of same organ system which may need different duration of antimicrobial therapy. * Lack of source control i.e lack of drainage of infected fluid collections, debridement of infected solid or necrotic tissue, removal of devices or foreign bodies, or definitive measures to correct anatomic derangements resulting in ongoing microbial contamination. This will be determined by investigator. * Need for subacute rehabilitation due to physical frailty either chronic, or from hospitalization. * Acute stroke during hospitalization. * Severe neutropenia- ANC \<500 or thrombocytopenia - platelet count \<50,000. * On prohibited concomitant medications

Design outcomes

Primary

Measure	Time frame	Description
Frequency of Clinically Assessed Cure, Completion (no Need for Further Parenteral Antimicrobial Therapy) or Transition to Suppressive Antimicrobial Therapy at 12 Weeks	12 weeks	One participant was enrolled in the study. The trial was terminated prematurely before any protocol-specified outcome assessments were completed. So cure or completion (no need for further parenteral antimicrobial therapy) or transition to suppressive antimicrobial therapy at 12 weeks could not be assessed, and no statistical analyses were performed.

Secondary

Measure	Time frame	Description
Frequency of Non-adherence to Antimicrobial Therapy (Lack of Follow up or Any Subsequent Scheduled Parenteral Antimicrobial Dose Administration)	12 weeks	One participant was enrolled in the study. The trial was terminated prematurely before any protocol-specified outcome assessments were completed. Consequently, no participants contributed evaluable data(Frequency of non-adherence to antimicrobial therapy) for this outcome measure, and no statistical analyses were performed.
Frequency of Hospital Readmission at 30 Days Post Discharge and at 90 Days Post Discharge	12 weeks	One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Proportion of Patients With Drug Related AE	12 weeks	One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Rate of Follow up at Scheduled in Person Medication for Opioid Use Disorder (MOUD) Visit and Frequency of Follow up/no Shows at Follow up Dosing Visits for MOUD at 12 Weeks	12 weeks	One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Proportion of Patients With Positive Urine Drug Screen	12 weeks	One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Evaluate Effect of Medication for Opioid Use Disorder (MOUD) Follow up on Cure/Completion or Transition to Suppressive Antimicrobial Therapy.	12 weeks	One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.
Rate of Direct Acting Antiviral (DAA) Initiation for Hepatitis C (HCV) in Patients Enrolled and Rate of DAA Completion and SVR for HCV in Patients Enrolled	6 months	One participant was enrolled. The study was terminated before protocol-specified outcome assessments were completed. Therefore, no participants contributed evaluable data for this outcome measure.

Countries

United States

Participant flow

Recruitment details

One patient screen failed and one patient opted out of the study after initial visit

Pre-assignment details